These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19960652)

  • 21. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical perspective of fusion inhibitors for treatment of HIV.
    Rockstroh JK; Mauss S
    J Antimicrob Chemother; 2004 May; 53(5):700-2. PubMed ID: 15044424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
    J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
    Hardy H; Skolnik PR
    Pharmacotherapy; 2004 Feb; 24(2):198-211. PubMed ID: 14998221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease.
    Montaner J; Guimaraes D; Chung J; Gafoor Z; Salgo M; DeMasi R
    HIV Clin Trials; 2005; 6(6):281-90. PubMed ID: 16566082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.
    Youle M; Cohen C; Katlama C; Kuritzkes D; Walmsley S
    Lancet; 2004 Sep 18-24; 364(9439):1036-7. PubMed ID: 15380959
    [No Abstract]   [Full Text] [Related]  

  • 27. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    Walmsley S; Henry K; Katlama C; Nelson M; Castagna A; Reynes J; Clotet B; Hui J; Salgo M; DeMasi R; Delehanty J
    J Infect Dis; 2003 Dec; 188(12):1827-33. PubMed ID: 14673761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
    Harris M; Larsen G; Montaner JS
    AIDS; 2008 Jun; 22(10):1224-6. PubMed ID: 18525270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enfuvirtide: a review of its use in the management of HIV infection.
    Oldfield V; Keating GM; Plosker G
    Drugs; 2005; 65(8):1139-60. PubMed ID: 15907147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
    Clotet B; Raffi F; Cooper D; Delfraissy JF; Lazzarin A; Moyle G; Rockstroh J; Soriano V; Schapiro J
    AIDS; 2004 May; 18(8):1137-46. PubMed ID: 15166529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
    Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The fusion inhibitor enfuvirtide in recent antiretroviral strategies.
    Makinson A; Reynes J
    Curr Opin HIV AIDS; 2009 Mar; 4(2):150-8. PubMed ID: 19339955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
    Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
    Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
    Hornberger J; Kilby JM; Wintfeld N; Green J
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Enfuvirtide: first drug of a new family of antiretroviral agents].
    Espona M; Ferrández O; Grau S; Carmona A
    Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfuvirtide (T-20): potentials and challenges.
    Foy K; Juethner SN
    J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.